Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36)

Diabetes Research and Clinical Practice

Volumn 109, Issue 3, 2015, Pages 485-492

  Yokoyama, H ^a   Araki, S ^b   Kawai, K ^c   Hirao, K ^d   Oishi, M ^e,p   Sugimoto, K ^f   Sone, H ^g   Maegawa, H ^b   Kashiwagi, A ^b   Doi, K ^h   Fukumoto, Y ⁱ   Iwasaki, K ^j   Kudo, M ^k   Minami, M ^l   Ogawara, H ^m   Takeda, H ⁿ   Miyazawa, K ^o   Takamura, H ^q   Takai, M ^r   Takahashi, C ^s   Takagi, H ^t   Wada, T ^u   more..

^a Jiyugaoka Medical Clinic   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c Kawai Clinic   (Japan)

^d HEC Science Clinic   (Japan)

^e Oishi Clinic   (Japan)

^f Sugimoto Clinic   (Japan)

^g NIIGATA UNIVERSITY   (Japan)

^h Doi Internal Medicine Clinic   (Japan)

ⁱ Fukumoto Clinic   (Japan)

^j Iwasaki Clinic of Internal Medicine   (Japan)

^k Kudo Internal Medicine Clinic   (Japan)

^l Minami Clinic   (Japan)

^m Akasaka Mental Clinic   (Japan)

ⁿ Oishi Clinic of Internal Medicine   (Japan)

^o Takeda Clinic   (Japan)

^p Miyazawa Clinic   (Japan)

^q Takamura Clinic   (Japan)

^r Takai Internal Medicine Clinic   (Japan)

^s Fuji Koyama Hospital   (Japan)

^t TOHO UNIVERSITY   (Japan)

^u Toyo Kohan Co   (Japan)

more..

Author keywords

Cardiovascular disease; Coronary heart disease; Mortality; Observational cohort; Pioglitazone; Stroke; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLADDER CANCER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FOLLOW UP; FRACTURE; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; MIDDLE AGED; MORTALITY; PHYSIOLOGY;

AGED; ALBUMINURIA; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84940786585     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.06.005     Document Type: Article

References (40)

1. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
2. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103:137-149.
3. Seshasai S.R., Kaptoge S., Thompson A.Di, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364:829-841. Emerging Risk Factors Collaboration.
4. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
5. Staels B., Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460-2470.
6. Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010, 70:1945-1961.
7. Schernthaner G., Currie C.J., Schernthaner G.H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 2013, 36(Suppl 2):S155-S161.
8. DeFronzo R.A., Eldor R., Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013, 36(Suppl 2):S127-S138.
9. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
10. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007, 298:1180-1188.
11. Yokoyama H., Katakami N., Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006, 37:2420-2427.
12. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
13. Yokoyama H., Matsushima M., Kawai K., Hirao K., Oishi M., Sugimoto H., et al. Low incidence of cardiovascular events in Japanese patients with Type 2 diabetes in primary care settings: a prospective cohort study (JDDM 20). Diabet Med 2011, 28:1221-1228.
14. Yokoyama H., Araki S., Haneda M., Matsushima M., Kawai K., Hirao K., et al. Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25). Diabetologia 2012, 55:1911-1918.
15. Matsuo S., Imai E., Horio M. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
16. D'Agostino R.B., Lee M.L., Belanger A.J., Cupples L.A., Anderson K., Kannel W.B. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990, 9:1501-1515.
17. Erdmann E., Song E., Spanheimer R., van Troostenburg de Bruyn A.R., Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab 2014, 16:63-74.
18. Yoshii H., Onuma T., Yamazaki T., Watada H., Matsuhisa M., Matsumoto M., et al. PROFIT-J Study Group. Effects of pioglitazone on macrovascular events in patients with type 2 diabetes mellitus at high risk of stroke: the PROFIT-J study. J Atheroscler Thromb 2014, 21:563-573.
19. Kaku K., Daida H., Kashiwagi A., Yamashina A., Yamazaki T., Momomura S., et al. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin 2009, 25:2925-2932.
20. Betteridge D., Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005, 48:2477-2481.
21. Gutierrez A.D., Sathyanarayana P., Konduru S., Ye Y., Birnbaum Y., Bajaj M. The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis 2012, 2(23):204-208.
22. Barseghian A., Gawande D., Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol 2011, 57:761-770.
23. Schulze M.B., Shai I., Rimm E.B., Li T., Rifai N., Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539.
24. Tsuchiya K., Akaza I., Yoshimoto T., Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. Endocrine J 2009, 56:691-698.
25. Pfützner A., Marx N., Lübben G., Langenfeld M., Walcher D., Konrad T., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
26. Permana P.A., Zhang W., Wabitsch M., Fischer-Posovszky P., Duckworth W.C., Reaven P.D. Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages. Am J Physiol Endocrinol Metab 2009, 296:E1076-E1084.
27. Subramanian V., Golledge J., Ijaz T., Bruemmer D., Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPARγ. Circ Res 2010, 107:953-958.
28. Ogasawara D., Shite J., Shinke T., Watanabe S., Otake H., Tanino Y., et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009, 73:343-351.
29. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008, 299:1561-1573.
30. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. J Am Med Assoc 2006, 296:2572-2581.
31. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32:219-226.
32. Stehouwer C.D., Nauta J.J., Zeldenrust G.C., Hackeng W.H., Donker A.J., den Ottolander G.J. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992, 340:319-323.
33. Yokoyama J., Sutoh N., Higuma T., Horiuchi D., Katoh C., Yokota T., et al. Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 2007, 22:146-151.
34. Aso Y., Hara K., Ozeki N., Yatsuka C., Nakano T., Matsumoto S., et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 2009, 85:147-152.
35. Kasliwal R., Wilton L.V., Shakir S.A. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf 2008, 31:839-850.
36. Kung J., Henry R.R. Thiazolidinedione safety. Expert Opin Drug Saf 2012, 11:565-579.
37. Azoulay L., Yin H., Filion K.B., Assayag J., Majdan A., Pollak M.N., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. Br Med J 2012, 344:e3645.
38. Perez A., Zhao Z., Jacks R., Spanheimer R. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009, 25:2915-2923.
39. Derosa G., Tinelli C., Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009, 11:1091109-1091119.
40. Tzoulaki I., Molokhia M., Curcin V., Little M.P., Millett C.J., Ng A., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. Br Med J 2009, 339:b4731.